“On the call, NP drew a distinction between “Commercialization” of LL, which means: labeling, advertising and selling the drug retail, versus charging for equipping hospitals with a supply to provide CSP at various hospitals on a large scale, at their discretion, throughout the Philippines.”
IMO, he’s drawing the distinction because he’s attempting to avoid paying the upfront payments ($6 million total) and royalties to AbbVie and Progenics. I imagine AbbVie and Progenics are watching and will want their share. CYDY cannot afford to do that at the moment, especially considering they may owe $4-5 million to the plaintiffs lawyers for the Delaware lawsuit.
“Let’s let this play out and see if there is truth in NP. I do not see how he can survive, as CEO, if this is not a significant milestone.”
NP was finished as CEO the second CD12 failed. He needs to gather his shares and retire and allow someone else to make him a very rich.